Jacobio 2022 Annual Results Investor Presentation

Jacobio Pharmaceuticals reported 2022 annual results highlighting multiple clinical-stage oncology programs including KRAS G12C inhibitor Glecirasib (JAB-21822), SHP2 inhibitor JAB-3312, and newly approved INDs for JAB-24114, JAB-BX102, and JAB-2485. The company advanced pivotal trials in NSCLC, demonstrated proof-of-concept in combination therapies for colorectal cancer and PDAC, and established collaborations with Merck on combination studies with cetuximab and pembrolizumab.